View Document Preview and Link Document Date: 2014-11-06 23:49:41 Open Document File Size: 340,27 KB Share Result on Facebook
City Dublin / Dysport / Canberra / / Company Patient Total / Allergan Australia Pty Ltd / / Country Australia / / Currency USD / / Event FDA Phase / / Facility In hospital / Bibliography Australian Institute of Health / / IndustryTerm injection site / co-dependent technology / draft protocol / final protocol / pharmaceuticals / health insurer / health insurance / clinical management algorithm / healthcare resources / draft decision analytic protocol / decision analytical protocol / / MedicalCondition overactive bladder / primary neurologic disorder / moderate urinary incontinence / bilateral blepharospasm / headaches / hemifacial spasm / headache / urge incontinence / urinary incontinence / urinary tract infection / ambulant cerebral palsy / spasmodic dysphonia / ambulant paediatric cerebral palsy / deformity / multiple sclerosis / bladder stones / benign prostatic hyperplasia / non-neurologic disease / equinovarus / idiopathic overactive bladder / slight urinary incontinence / spinal cord injury / dynamic equinovarus / neurogenic overactive bladder / dynamic foot deformity / cerebral palsy / spasmodic torticollis / urethral stricture / cervical dystonia / blepharospasm / pelvic tumours / stroke / migraine / juvenile cerebral palsy / specifically hemifacial spasm / coughing / identifiable neurologic disorder / overactive bladder syndrome / chronic migraine / VII nerve disorders / strabismus / dystonia / benign blepharospasm / idiopathic overactive bladder syndrome / bladder spasms / severe primary hyperhidrosis / / MedicalTreatment behavioural therapies / antibiotics / Behavioural therapy / physiotherapy / BOTOX / occupational therapy / surgeries / major surgery / drug therapies / Drug therapy / / Movie Quality of life / / Organization In hospital / Therapeutic Goods Administration / Bibliography Australian Institute of Health and Welfare / Medicare / Australian Institute of Health and Welfare / NHMRC Clinical Trials Centre / Clinical Trials Centre / Department of Health / Medical Services Advisory Committee / / Person Ageing / BOTULINUM TOXIN / / Position Minister / / Product PERIURETHRAL OR TRANSURETHRAL INJECTION / Botox injection / Transurethral injection / BOTOX® injection / tolterodine / Transurethral / BOTOX® / BOTOX / / RadioStation Clin N Am 37 / / Technology draft decision analytic protocol / ultrasound / co-dependent technology / draft protocol / 1221 Consultation Decision Analytical Protocol / decision analytical protocol / supportive care Clinical management algorithm / clinical management algorithm / final protocol / / SocialTag 
Application 1221 Consultation Decision Analytical Protocol (DAP) to guide the assessment of Transurethral injection of BOTOX® (botulinum toxin) for the treatment of urinary incontinence due to neurogenic detrusor overac